Drugs / SC291
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06294236 | Apr 2024 → Dec 2027 expected | granulomatosis with polyangiitis, microscopic polyangiitis, systemic lupus erythematosus | Sana Biotechnology | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05878184 | May 2023 → Nov 2025 overdue | B-cell chronic lymphocytic leukemia | Sana Biotechnology | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SC291 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05878184 ↗ |
| Modality | Cell therapy | “SC291 is an allogeneic CAR-T cell therapy” NCT05878184 ↗ |
| Route | Intravenous | “SC291 administered intravenously (IV)” NCT05878184 ↗ |
| Target | CD19 | “CD19-directed CAR T Cell Therapy” NCT06294236 ↗ |